The heparan sulfate (HS) proteoglycan, syndecan-1, plays a major role in multiple myeloma (MM) by concentrating heparin-binding growth factors on the surface of MM cells (MMC). Using Affymetrix microarrays and real-time RT-PCR, we show that the gene encoding heparanase (HPSE), an enzyme that cleaves HS-chains, is expressed by 11/19 myeloma cell lines (HMCLs). In HSPE-positive HMCLs, syndecan-1 gene expression and production of soluble syndecan-1, unlike expression of membrane syndecan-1, were significantly increased. Knockdown of HPSE by siRNA resulted in a decrease of syndecan-1 expression and soluble syndecan-1 production without affecting membrane syndecan-1 expression. Thus, HPSE influences expression and shedding of syndecan-1. Contrary to HMCLs, HPSE is expressed in only 4/39 primary MMC samples, whereas it is expressed in 36/39 bone marrow (BM) microenvironment samples. In the latter, HPSE is expressed at a median level in polymorphonuclear cells and T cells; it is highly expressed in monocytes and osteoclasts. Affymetrix data were validated at the protein level, both on HMCLs and patient samples. We report for the first time that a gene's expression mainly in the BM environment, i.e. HSPE, is associated with a shorter event-free survival of newly diagnosed myeloma patients treated with highdose chemotherapy and stem cell transplantation. Our study suggests that clinical inhibitors of HPSE could be beneficial for patients with MM.
Introduction
Multiple myeloma (MM) is a B cell neoplasia characterized by the growth of a clone of malignant plasma cells (PCs) in the bone marrow. Syndecan-1, a transmembrane heparan sulfate proteoglycan (HSPG), is expressed by both normal and malignant PCs and is now widely used to identify and purify these cells 1, 2 . We have previously shown that among the 10 known HSPGs, syndecan-1 is the main one present on the surface of PC 3 . Syndecan-1 binds to extracellular matrix proteins and to growth factors that have a HS-binding domain, thus promoting their activity 4 . In particular, it has been shown that syndecan-1 mediates hepatocyte growth factor (HGF) binding and promotes c-met signalling in myeloma cells (MMC) 5 
¡
We and others have shown that syndecan-1 is necessary for the MMC growth activity of HGF and epidermal growth factor (EGF)-family ligands that have a HS-binding domain 3, [5] [6] [7] . Syndecan-1 concentrates high amounts of growth factors at the cell surface and then likely facilitates the activation of their receptors. The ectodomain of syndecan-1 can be cleaved from the MMC surface into a soluble form by metalloproteinases that remain to be identified in MMC 8, 9 . Soluble syndecan-1 is present at high levels in the serum of patients with MM and is an indicator of poor prognosis 8, 10, 11 . It also accumulates in the bone-marrow microenvironment where it might sequester heparin-binding growth factors in the proximity of the tumor 12 . Accordingly, it has been shown that soluble syndecan-1, which retains biologically active HS chains, can promote tumor growth in a myeloma SCID-hu mouse model 13 .
The function of HSPGs is regulated by extracellular enzymes that modulate the structure of HS-chains. One such enzyme is heparanase (HPSE), encoded by only one gene in mammalian cells 14, 15 . HPSE is an endoglucuronidase that cleaves HS chains at only a few sites, resulting in HS fragments of 10-20 sugar units long 14, 16 . These fragments are long enough to bind growth factors and can be more biologically active than the native HS chains 17 . HPSE is overexpressed in numerous tumors where it increases the angiogenic and metastatic potential of tumor cells 18 . In patients with MM, HPSE activity could be found in bone marrow aspirates 19 . HPSE increases microvessel density 19 and promotes growth and metastasis of MMC to bone in vivo 20 .
Here we show for the first time that HPSE is involved in the regulation of syndecan-1 gene expression and controls the production of soluble syndecan-1 in myeloma cell lines. In patients with newly-diagnosed MM, HPSE is expressed mainly by cellfractions of the bone marrow microenvironment, especially monocytes and osteoclasts, but weakly by MMC. High HPSE expression in bone marrow of patients with MM correlates with a shorter event-free survival (EFS) and overall survival (OAS).
Materials and Methods

Cell samples
Whole bone marrow samples (WBM) and purified MMC were obtained from 39
patients with MM at diagnosis (presenting at the university Hospitals of Heidelberg, Germany and Montpellier, France) after written informed consent was given. These patients were treated with high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). The study was approved by the ethics boards of both newly-diagnosed MM, BM T cells, monocytes, and polymorphonuclear cells were purified as described previously 21 . Osteoclasts and BM stromal cells (BMSCs) were generated in vitro as described 21 . Immature dendritic cells (DCs) were generated from leukapheresis products of MM patients, as previously described 22 . 23, 24 . They were routinely maintained in RPMI1640, 10% fetal calf serum, and 2 ng/ml of IL-6 (Abcys, Paris, France). U266, SKMM, OPM2, LP1, and RPMI8226 HMCLs were purchased from ATTC (Rockville, MD, USA).
Microarray hybridization
RNA was extracted with the RNeasy Kit (Qiagen, Hilden, Germany), the SV-total RNA extraction kit (Promega, Mannheim, Germany), and Trizol (Invitrogen, Karlsruhe, Germany) in accordance with the manufacturer's instructions. Biotinylated complementary RNA (cRNA) was amplified with double in vitro transcription, according to the Affymetrix small sample labeling protocol (Affymetrix, Santa Clara, CA, USA). The biotinylated cRNA was fragmented and hybridized to the human genome U133 set (for HMCLs) or U133 Plus 2.0 (for patient samples) microarrays according to the manufacturer's instructions (Affymetrix). Fluorescence intensities were quantified and analyzed using the GCOS software (Affymetrix).
Real-time reverse transcriptase-polymerase chain reaction
RNA was extracted using the RNeasy Kit (Qiagen). We generated cDNA from 100 ng of total RNA using Superscript II reverse transcriptase (Invitrogen, Cergy-Pontoise, France). For real-time RT-PCR, we used Assay-on-Demand primers and probes and the TaqMan Universal Master Mix from Applied Biosystems (Courtaboeuf, France)
according to the manufacturer's instructions. Gene expression was measured using the ABI Prism 7000 Sequence Detection System. For comparative analysis of gene expression, data were obtained by using the ∆∆Ct method derived from a mathematical approach previously described. For each sample, the C T value for the gene of interest was determined and normalized to its respective C T value for beta2-microglobulin (B2M) (∆C T =C T -C T B2M) or GAPDH (∆C T =C T -C T GAPDH) , and compared to a cell type used as a positive control. The formula used was: 1/2 ∆CT sample -∆CT control cell line . Ct values were collected during the log phase of the cycle.
The results were expressed as the relative mRNA levels to control cell sample mRNA.
Western blot.
Cells were lysed in 10 mM Tris-HCl (pH 7.05), 50 mM NaCl, 50 mM NaF, 30 mM sodium pyrophosphate (NaPPi), 1% triton X-100, 5 µM ZnCl 2 , 100 µM Na 3 VO4, 1 mM DTT, 20 mM β-glycerophosphate, 20 mM p-nitrophenolphosphate (PNPP), 20 µg/ml aprotinin, 2.5 µg/ml leupeptin, 0.5 mM PMSF, 0.5 mM benzamidine, 5 µg/ml pepstatin, and 50 nM okadaic acid. Lysates were resolved on 12% sodium dodecyl sulfate-polyacrylamide by gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Schleicher and Schuell, Kassel, Germany statistical significance of differences in event-free survival between groups of patients was estimated by the log-rank test. An event was defined as relapse or death (for EFS) or as death (for OAS). The survival curves were plotted using the Kaplan-Meier method.
Results
HPSE expression in myeloma cell lines.
Expression of HPSE was evaluated with Affymetrix U133 set microarrays on 19
HMCLs. Eleven of 19 HMCLs displayed a "present" call for the HPSE probeset (HPSE pos ) with a median expression level of 90 (range 48-448, Figure 1A ). The other 8 cell lines displayed an "absent" call (HPSE neg ) with a low expression level (median=6, range=2-28) ( Figure 1A ). The call ("present" or "absent") is determined by Affymetrix GCOS-software and indicates whether a gene is reliably expressed or not 25 . The data were validated by real-time RT-PCR (r = 0.87, P < .01, Figure 1B ). HPSE expression at the protein level was evaluated by Western blot analysis. HPSE was detected in 3/3 HMCLs with a "present" Affymetrix detection call (U266, XG-2
and XG-20), but not in those with an "absent" Affymetrix call (XG-1 and XG-7, Figure   1C ). The 50 kDa MW active form of the enzyme was predominant, but the 65 kDa MW proenzyme could also be detected ( Figure 1C) . Furthermore, HMCLs were tested for HPSE activity using an assay based on the measurement of HPSEinduced degradation of biotinylated-HS fragments (b-HS). In this assay, undegraded b-HS is bound to an FGF-coated plate and bound b-HS is detected by HRPstreptavidin. The b-HS fragment is specifically designed so that it does not bind to FGF when degraded by HPSE, thus resulting in a lower HRP signal. HPSE activity was high in the HPSE pos XG-2 and XG-20 HMCLs (0.6 U/ml and 0.82 U/ml, respectively). It was intermediate in U266 (0.14 U/ml) and below the detection limit (0.05 U/ml) in the HPSE neg XG-1 and XG-7 HMCLs ( Figure 1D ). Thus, HPSE activity correlated with HPSE expression in HMCLs.
Gene expression profile associated with HPSE expression in myeloma cell lines.
As the HPSE signal expression in HMCLs is either present or absent, these HMCLs are of interest to study the biological function of HPSE in MM. We compared the gene expression profile of the 11 HPSE pos HMCLs with those 8 HPSE neg HMCLs in a supervised analysis performed with the SAM software using 1000 permutations.
Only probesets that were "present" in more than 3 samples and had at least a 2-fold change in expression were retained in the analysis. This resulted in a list of 41
probesets that were all overexpressed in HPSE pos HMCLs, with a false discovery rate (FDR) of 7.7%. These 41 probesets interrogated 33 genes and 3 expressed sequence tags (EST), which are listed in Table 1 . Interestingly, syndecan-1 was among those 41 genes.
Correlation between soluble syndecan-1 production and HPSE gene expression in HMCL.
As shown in Figure HPSE non-targeting siRNA-co did not affect syndecan-1 or GAPDH expression. We then investigated whether targeting HPSE mRNA may influence membrane syndecan-1 expression or soluble syndecan-1 production. Electroporation of HPSEspecific siRNA had no effect on the expression of membrane syndecan-1 ( Figure   3B ). In contrast, HPSE downregulation resulted in nearly 80% inhibition (P < .01) of soluble syndecan-1 production ( Figure 3C ). No inhibition was found with the control siRNA ( Figure 3C Figure 4A ). The HPSE expression in the WBM samples (median=76, range=25-221) was 7.6-fold higher (P < .0001) than that found in the corresponding MMC (median=10, range=8-26). Furthermore, HPSE had an Affymetrix "present call"
in 92% (36/39) of the WBM samples, whereas it had a "present call" in only 10% Figure 6B , panels d-e). In addition, a strong staining of megakaryocytes was found ( Figure 6B, panel f) . Regarding MMC, HPSE expression was heterogeneous among patients. Data are summarized in Table 3 . HPSE expression lacked in the MMC of 3/20 patients (as illustrated for one patient in Figure 6B, panel g ). In the majority of the patients, a strong heterogeneity was found with few positively stained MMC close to negative tumor cells ( Figure 6B , panels h-i, and Table 3 ). This heterogeneous HPSE expression among MMC is in agreement with previously published data 19 . HPSE expression level in the positively stained MMC was low. In 2/20 samples, we found a higher percentage of more intensely labelled MMC ( Figure 6B , panel j, and Table 3 ). Of note, a strong nuclear staining appeared in the MMC from those two patients. patients into two groups according to HPSE expression in MMC did not result in any significant differences in the EFS or OAS between the two groups ( Figure 7B ). This is in agreement with the low HPSE expression in MMC compared to that found in the microenvironment. Those data indicate that HPSE expression in the WBM, but not in the MMC, is linked to the prognosis of myeloma patients.
Discussion
Given the major role of the syndecan- Figure 6B ) nor in a larger set of MMC from 104 newly-diagnosed patients (data not shown). This again emphasizes that HPSE is mainly expressed by the BM environment and that this expression is biologically relevant. This is the first study showing that a gene measured in the bone marrow microenvironment has prognostic value in MM.
The fact that HPSE controls syndecan-1 expression and soluble syndecan-1 production may explain at least in part the poor prognosis of HSPE high patients, as increased levels of soluble syndecan-1 have been described as a bad prognostic factor in patients with MM 10, 11 . Soluble syndecan-1 can promote tumor growth in a murine model 13 , presumably because it can sequester heparin binding growth factors that support MMC growth as well as angiogenic factors like VEGF 5, 29, 30 , thus providing MMC with an increased amount of growth factors. Consistently, Kelly et al have shown HPSE to increase microvessel density 19 , which in turn correlates with poor prognosis in MM 31, 32 .
In an independent series of 20 newly-diagnosed patients,
we did not find any significant correlation between HPSE expression in the WBM and Accordingly, it has been shown that HPSE can release HS-bound growth factors such as FGF2 from the extracellular matrix 35 . Alternatively, HPSE may improve the HS-mediated effect of heparin binding-growth factors. Indeed, small fragments resulting from the HPSE cleavage were reported to be more biologically active than the native HS chains from which they are derived 17 . Finally, besides its endoglycosidase activity, it is now becoming clear that HPSE might have other nonenzymatic functions which may also have an impact on tumor growth. It was not within the scope of our study to elucidate the mechanism involved in the regulation of syndecan-1 gene expression and shedding by HPSE, but one can speculate that it might involve such non-enzymatic functions. These non-enzymatic functions include stimulation of endothelial cell invasion via AKT pathway activation 36 , enhanced cell adhesion of glioma 37 , lymphoma 38 and T cells mediated by β1-integrin
39
, and induction of VEGF expression 40 . These mechanisms are poorly understood but might involve a yet undefined receptor that could lead to activation of transduction pathways and mediate diverse biological effects.
Altogether, these data provide evidence that HPSE can modulate syndecan-1 activity through the cleavage of its HS chains but also through the regulation of syndecan-1 mRNA expression and shedding. HPSE, mainly produced by the environment, is an indicator of poor prognosis for MM patients. Therefore, HPSE inhibitors like PI-88 which is currently in clinical trials 41 , will be of interest for the treatment of patients with MM. 
